Scientists build a biobank to crack the mystery of CAR-T cell failure
NCT ID NCT04290000
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study collects extra blood and bone marrow samples from people receiving CAR-T cell therapy for lymphoma or acute lymphoblastic leukemia. The goal is to build a biobank that researchers can use to investigate why about half of patients do not respond to this treatment. Participants will give samples at specific times during their treatment journey, including during apheresis, at reinfusion, and during follow-up. No new treatments are being tested; the focus is on gathering biological material for future research.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CAR-T cells (Yescarta and Kymriah)
What this could lead to
If successful, this sample bank could help researchers identify why CAR-T therapy fails in some patients, pointing toward ways to improve treatment.
What could go wrong
This is a sample-collection study, not a treatment trial. It will not directly benefit participants and may not yield clear answers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Département d'hématologie clinique
RECRUITINGMontpellier, 34295, France
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••